Trials / Completed
CompletedNCT01877005
A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 33 (actual)
- Sponsor
- The Lymphoma Academic Research Organisation · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase II study to assess the efficacy of 6 cycles of oral JAK1/2 inhibitor ruxolitinib in patients with advanced Hodgkin's lymphoma for whom no curative option is available.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ruxolitinib |
Timeline
- Start date
- 2013-07-04
- Primary completion
- 2015-06-01
- Completion
- 2018-06-12
- First posted
- 2013-06-13
- Last updated
- 2018-08-22
Locations
10 sites across 2 countries: Belgium, France
Source: ClinicalTrials.gov record NCT01877005. Inclusion in this directory is not an endorsement.